Boston Scientific Corporation $BSX Stock Bought by Citizens Financial Group Inc. RI

Key Points

• Citizens Financial Group increased its Boston Scientific position by 183.1% in the third quarter, bringing its holdings to 62,102 shares valued at approximately $2.7 million. Institutional investors collectively own 89.07% of the company.
• Boston Scientific’s latest quarterly results exceeded expectations, with EPS of $0.86 versus an $0.83 estimate and revenue of $5.44 billion, up 7.5% year over year. The company provided fiscal 2026 EPS guidance of $3.28 to $3.32.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and average price target of $68.07, despite several recent target-price reductions. Company insiders have also purchased 194,522 shares worth roughly $9.4 million over the past 90 days.

Citizens Financial Group Inc. RI lifted its position in Boston Scientific Corporation (NYSE:BSX - Free Report) by 183.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 62,102 shares of the medical equipment provider's stock after acquiring an additional 40,168 shares during the quarter. Citizens Financial Group Inc. RI's holdings in Boston Scientific were worth $2,711,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. BlackRock Inc. purchased a new stake in shares of Boston Scientific during the 2nd quarter worth $5,534,781,000. Primecap Management Co. CA acquired a new stake in Boston Scientific in the second quarter valued at approximately $2,156,233,000. Janus Henderson Group PLC increased its position in shares of Boston Scientific by 31.0% during the first quarter. Janus Henderson Group PLC now owns 16,497,366 shares of the medical equipment provider's stock worth $1,035,202,000 after purchasing an additional 3,907,981 shares in the last quarter. Amundi increased its position in Boston Scientific by 13.8% during the 1st quarter. Amundi now owns 14,122,913 shares of the medical equipment provider's stock valued at $886,213,000 after buying an additional 1,707,754 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership raised its stake in Boston Scientific by 25.9% in the first quarter. Arrowstreet Capital Limited Partnership now owns 13,891,668 shares of the medical equipment provider's stock valued at $871,702,000 after buying an additional 2,856,040 shares during the last quarter. Institutional investors own 89.07% of the company's stock.

Insiders Place Their Bets

In related news, Director David C. Habiger purchased 2,100 shares of Boston Scientific stock in a transaction dated Wednesday, August 5th. The shares were acquired at an average cost of $47.59 per share, with a total value of $99,939.00. Following the purchase, the director owned 17,160 shares of the company's stock, valued at approximately $816,644.40. The trade was a 13.94% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Edward J. Ludwig acquired 5,000 shares of the stock in a transaction that occurred on Friday, July 31st. The shares were bought at an average cost of $45.48 per share, with a total value of $227,400.00. Following the transaction, the director directly owned 30,359 shares in the company, valued at $1,380,727.32. This trade represents a 19.72% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have bought 194,522 shares of company stock valued at $9,385,210 over the last ninety days. Company insiders own 0.34% of the company's stock.

Boston Scientific Trading Down 0.2%

BSX stock opened at $45.60 on Tuesday. The business's 50-day moving average is $45.54 and its 200 day moving average is $58.24. Boston Scientific Corporation has a 12-month low of $41.38 and a 12-month high of $105.65. The stock has a market cap of $66.08 billion, a price-to-earnings ratio of 18.46, a PEG ratio of 1.10 and a beta of 0.58. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating analysts' consensus estimates of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%. The company had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. During the same quarter last year, the firm posted $0.75 EPS. The firm's revenue for the quarter was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, sell-side analysts anticipate that Boston Scientific Corporation will post 3.24 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have weighed in on BSX shares. TD Cowen reissued a "buy" rating on shares of Boston Scientific in a research report on Tuesday, October 20th. Barclays raised Boston Scientific to a "hold" rating in a report on Wednesday, October 7th. Sanford C. Bernstein reissued an "outperform" rating and set a $54.00 target price (down from $60.00) on shares of Boston Scientific in a report on Saturday, October 3rd. BTIG Research cut their price target on Boston Scientific from $60.00 to $56.00 and set a "buy" rating on the stock in a research report on Wednesday, September 9th. Finally, Leerink Partners reduced their price target on Boston Scientific from $60.00 to $55.00 in a research report on Friday, October 9th. One research analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat, Boston Scientific has a consensus rating of "Moderate Buy" and an average target price of $68.07.

Boston Scientific Company Profile

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.